<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495014</url>
  </required_header>
  <id_info>
    <org_study_id>DIX109981</org_study_id>
    <nct_id>NCT00495014</nct_id>
  </id_info>
  <brief_title>Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects</brief_title>
  <official_title>A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study represents the second Phase 1 study with GSK376501 and the goal is to further&#xD;
      evaluate its safety and tolerability. The way the human body processes GSK376501 will also be&#xD;
      determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose</measure>
    <time_frame>following each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GSK376501 following 1 day (Part A) or 14 days (Part B) of dosing</measure>
    <time_frame>following 1 day (Part A) or 14 days (Part B) of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK376501 plasma levels to derive pharmacokinetic parameters following single and repeat doses for 14 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard markers that may serve as possible surrogates of volume expansions with GSK376501.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight following 14 days of repeat dosing with GSK376501.</measure>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK376501</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <other_name>GSK376501</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is healthy and overweight/obese, defined as having a body mass index&#xD;
             greater than 25 but less than 35kg/m2, inclusive.&#xD;
&#xD;
          -  The subject is an adult male or a female of non-childbearing potential between the age&#xD;
             of 18 and 65 years, inclusive, at the time of signing informed consent.&#xD;
&#xD;
          -  The subject and their partner are willing to use double-barrier method of&#xD;
             contraception from the first day of study drug administration until 5 half-lives of&#xD;
             the drug have elapsed following the last day of study drug administration.&#xD;
&#xD;
          -  The subject demonstrates an ECG with values within ranges specified in the protocol at&#xD;
             screening or baseline.&#xD;
&#xD;
          -  The subject is capable of giving written informed consent, which includes the ability&#xD;
             to read, comprehend and comply with the protocol requirements and restrictions as&#xD;
             described in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any&#xD;
             medication that is chemically related to the study drug or a history of drug or other&#xD;
             allergy that, in the opinion of the physician responsible, contraindicates their&#xD;
             participation in the study.&#xD;
&#xD;
          -  Has a known allergy to any of the tablet formulation excipients of GSK376501 or&#xD;
             pioglitazone (as applicable).&#xD;
&#xD;
          -  Has sensitivity to heparin or history of heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Has a history of alcohol abuse or dependence within 12 months prior to the study.&#xD;
&#xD;
          -  Has a positive alcohol test at screening or baseline and/or is unwilling to abstain&#xD;
             from alcohol for 72 hours prior to the start of dosing until discharged from the&#xD;
             clinic and for 72 hours prior to the follow-up visit.&#xD;
&#xD;
          -  Is unwilling to abstain from caffeine- or xanthine-containing products for 24 hours&#xD;
             prior to each dose and throughout each in-house period, and for 24 hours prior to the&#xD;
             follow-up visit.&#xD;
&#xD;
          -  The subject smokes or has used tobacco or nicotine-containing products within the 6&#xD;
             months prior to the study, or is positive for urine cotinine at screening or at&#xD;
             baseline.&#xD;
&#xD;
          -  Is unwilling to refrain from the use of tobacco or illicit drugs during the trial,&#xD;
             and/or tests positive for urine cotinine or drugs of abuse at screening or at&#xD;
             baseline. At minimum, the list of drugs or classes of drugs that will be screened for&#xD;
             include the following: amphetamines, barbiturates, benzoylecgonine, benzodiazepines,&#xD;
             cannabinoids, cotinine, and opiates.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood in excess of 500 ml&#xD;
             within a 56 day period.&#xD;
&#xD;
          -  Has a systolic blood pressure outside the range of 140 to 90mmHg, a diastolic blood&#xD;
             pressure outside the range of 90 to 60mmHg and/or a heart rate outside the range of 90&#xD;
             to 45bpm, inclusive, at screening or at baseline.&#xD;
&#xD;
          -  Experiencing clinically significant ECG abnormalities at screening or at baseline.&#xD;
&#xD;
          -  Has a history or current evidence of a positive HIV test.&#xD;
&#xD;
          -  Has a history of or a positive pre-study Hepatitis B surface antigen or positive&#xD;
             Hepatitis C antibody result within 3 months of screening.&#xD;
&#xD;
          -  Has laboratory safety screening tests outside of ranges specified in the protocol at&#xD;
             screening or at baseline. T.&#xD;
&#xD;
          -  Pregnant or lactating women, or woman of childbearing potential.&#xD;
&#xD;
          -  Has a history of rhabdomyolysis.&#xD;
&#xD;
          -  Has congestive heart failure or a history of congestive heart failure with New York&#xD;
             Heart Association Class I-IV symptoms&#xD;
&#xD;
          -  Has a history of thyroid dysfunction or an abnormal thyroid function test as assessed&#xD;
             by TSH at screening.&#xD;
&#xD;
          -  Has a history or current evidence of sleep apnea.&#xD;
&#xD;
          -  Has had previous exposure to GSK376501, with the exception of subjects randomized into&#xD;
             a previously completed study with GSK376501 may participate only in the cohort&#xD;
             evaluating pioglitazone.&#xD;
&#xD;
          -  Has had treatment with any other new molecular entity (investigational drug) during&#xD;
             the previous 30 days or 5 half-lives, or twice the duration of the biological effect&#xD;
             of the drug (whichever is longer), prior to the first dose of current study&#xD;
             medication. For the purposes of this study, a new molecular entity is defined as any&#xD;
             compound that has not yet reached Phase 3 development. The washout is defined from&#xD;
             last dose of study medication in the previous study until the first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Has been exposed to more than four new molecular entities within 12 months prior to&#xD;
             the first dosing day.&#xD;
&#xD;
          -  Has used the following prescription or non-prescription medications within 14 days or&#xD;
             5 half lives, whichever is longer, prior to the first dose of study medication:&#xD;
             vitamins (at a dose greater than the recommended daily allowance), or dietary or&#xD;
             herbal supplements, including St. John's Wort.&#xD;
&#xD;
          -  Is unable or unwilling to discontinue use of acetaminophen 72 hours prior to each dose&#xD;
             and throughout each in-house period and no use within 72 hours of the follow-up visit.&#xD;
&#xD;
          -  Requires the use of a prohibited medication .&#xD;
&#xD;
          -  Is unable or unwilling to abstain from the consumption of grapefruit or grapefruit&#xD;
             juice for 7 days prior to the first dose of study medication until the final&#xD;
             pharmacokinetic sample has been collected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 15, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>GSK376501,</keyword>
  <keyword>Single Dose,</keyword>
  <keyword>Dose Escalation,</keyword>
  <keyword>Healthy Overweight/Obese Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

